Skip to main content

Advertisement

SpringerLink
Log in

Targeting CD30 in Anaplastic Large Cell Lymphoma

  • T-Cell and Other Lymphoproliferative Malignancies (C Dearden, Section Editor)
  • Published:
Current Hematologic Malignancy Reports Aims and scope Submit manuscript

Abstract

Anaplastic large cell lymphoma (ALCL) is a lymphoid neoplasm characterized by strong and uniform expression of the CD30 antigen on the cell surface. Current standard frontline therapy of ALCL is anthracycline-based combination chemotherapy, usually CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) or CHOP-like regimens. Despite aggressive chemotherapy a significant number of patients relapse. Newer agents and strategies are needed in the management of this challenging disease especially in ALK-negative and high-risk ALK-positive patients who tend to have a poor prognosis. In this review we discuss the different approaches to targeting CD30 including naked antibodies, “enhanced antibodies”, antibody drug–toxin conjugates, radioimmunoconjugates, CD30-ligand–toxin conjugates, bispecific antibodies and T cell-based immune therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC; 2008.

    Google Scholar 

  2. Savage KJ, Harris NL, Vose JM, Ullrich F, Jaffe ES, Connors JM, et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood. 2008;111(12):5496–504. doi:10.1182/blood-2008-01-134270.

    Article  PubMed  CAS  Google Scholar 

  3. Zinzani PL, Bendandi M, Martelli M, Falini B, Sabattini E, Amadori S, et al. Anaplastic large-cell lymphoma: clinical and prognostic evaluation of 90 adult patients. J Clin Oncol. 1996;14(3):955–62.

    PubMed  CAS  Google Scholar 

  4. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med. 1993;328(14):1002–6. doi:10.1056/NEJM199304083281404.

    Article  PubMed  CAS  Google Scholar 

  5. Simon A, Peoch M, Casassus P, Deconinck E, Colombat P, Desablens B, et al. Upfront VIP–reinforced–ABVD (VIP–rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS–LTP95. Br J Haematol. 2010;151(2):159–66.

    Article  PubMed  Google Scholar 

  6. Zelenetz AD, Hamlin P, Kewalramani T, Yahalom J, Nimer S, Moskowitz CH. Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin’s lymphoma. Ann Oncol. 2003;14 suppl 1:i5–10. doi:10.1093/annonc/mdg702.

    Article  PubMed  Google Scholar 

  7. Velasquez W, Cabanillas F, Salvador P, McLaughlin P, Fridrik M, Tucker S, et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood. 1988;71(1):117–22.

    PubMed  CAS  Google Scholar 

  8. Velasquez WS, McLaughlin P, Tucker S, Hagemeister FB, Swan F, Rodriguez MA, et al. ESHAP – an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol. 1994;12(6):1169–76.

    PubMed  CAS  Google Scholar 

  9. O'Connor OA, Pro B, Pinter-Brown L, Bartlett N, Popplewell L, Coiffier B, et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol. 2011;29(9):1182–9. doi:10.1200/jco.2010.29.9024.

    Article  PubMed  Google Scholar 

  10. Piekarz RL, Frye R, Prince HM, Kirschbaum MH, Zain J, Allen SL, et al. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood. 2011;117(22):5827–34. doi:10.1182/blood-2010-10-312603.

    Article  PubMed  CAS  Google Scholar 

  11. Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, et al. Results from a pivotal, open-label, phase ii study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol. 2012;30(6):631–6. doi:10.1200/jco.2011.37.4223.

    Article  PubMed  CAS  Google Scholar 

  12. Dürkop H, Latza U, Hummel M, Eitelbach F, Seed B, Stein H. Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease. Cell. 1992;68(3):421–7. doi:10.1016/0092-8674(92)90180-k.

    Article  PubMed  Google Scholar 

  13. Stein H, Mason D, Gerdes J, O'Connor N, Wainscoat J, Pallesen G, et al. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood. 1985;66(4):848–58.

    PubMed  CAS  Google Scholar 

  14. Falini B, Pileri S, Pizzolo G, Durkop H, Flenghi L, Stirpe F, et al. CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood. 1995;85(1):1–14.

    PubMed  CAS  Google Scholar 

  15. Horie R, Watanabe T. CD30: expression and function in health and disease. Semin Immunol. 1998;10(6):457–70. doi:10.1006/smim.1998.0156.

    Article  PubMed  CAS  Google Scholar 

  16. Pallesen G, Hamilton-Dutoit SJ. Ki-1 (CD30) antigen is regularly expressed by tumor cells of embryonal carcinoma. Am J Pathol. 1988;133(3):446–50.

    PubMed  CAS  Google Scholar 

  17. Gruss H, Boiani N, Williams D, Armitage R, Smith C, Goodwin R. Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines. Blood. 1994;83(8):2045–56.

    PubMed  CAS  Google Scholar 

  18. Aizawa S, Nakano H, Ishida T, Horie R, Nagai M, Ito K, et al. Tumor necrosis factor receptor-associated factor (TRAF) 5 and TRAF2 are involved in CD30-mediated NFκB activation. J Biol Chem. 1997;272(4):2042–5. doi:10.1074/jbc.272.4.2042.

    Article  PubMed  CAS  Google Scholar 

  19. Mir SS, Richter BWM, Duckett CS. Differential effects of CD30 activation in anaplastic large cell lymphoma and Hodgkin disease cells. Blood. 2000;96(13):4307–12.

    PubMed  CAS  Google Scholar 

  20. Ansell SM, Horwitz SM, Engert A, Khan KD, Lin T, Strair R, et al. Phase I/II Study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. J Clin Oncol. 2007;25(19):2764–9. doi:10.1200/jco.2006.07.8972.

    Article  PubMed  CAS  Google Scholar 

  21. Bartlett NL, Younes A, Carabasi MH, Forero A, Rosenblatt JD, Leonard JP, et al. A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies. Blood. 2008;111(4):1848–54. doi:10.1182/blood-2007-07-099317.

    Article  PubMed  CAS  Google Scholar 

  22. Forero-Torres A, Leonard JP, Younes A, Rosenblatt JD, Brice P, Bartlett NL, et al. A phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol. 2009;146(2):171–9. doi:10.1111/j.1365-2141.2009.07740.x.

    Article  PubMed  CAS  Google Scholar 

  23. Hammond PW, Vafa O, Jacinto J, Vielmetter J, Karki S, Yoder S, et al. A humanized anti-CD30 monoclonal antibody, XmAbTM2513, with enhanced in vitro potency against CD30-positive lymphomas mediated by high affinity Fc-receptor binding. Blood (ASH Annual Meeting Abstracts). 2005;106:Abstract 1470.

  24. Blum K, Smith M, Fung H, Zalevsky J, Combs D, Ramies D, et al. (editors) Phase I study of an anti-CD30 Fc engineered humanized monoclonal antibody in Hodgkin lymphoma (HL) or anaplastic large cell lymphoma (ALCL) patients: safety, pharmacokinetics (PK), immunogenicity, and efficacy. J Clin Oncol. 2009;27(15s). Abstract 8531.

    Google Scholar 

  25. Cardarelli PM, Moldovan-Loomis M-C, Preston B, Black A, Passmore D, Chen T-H, et al. In vitro and in vivo characterization of MDX-1401 for therapy of malignant lymphoma. Clin Cancer Res. 2009;15(10):3376–83. doi:10.1158/1078-0432.ccr-08-3222.

    Article  PubMed  CAS  Google Scholar 

  26. Thertulien R, Frankel A, Evens A, Kaufman J, Horwitz S, Assad A, et al. A phase I, open-label, dose-escalation, multidose study of MDX-1401 (defucosylated human antiCD30 monoclonal antibody) in patients with CD30-positive refractory/relapsed Hodgkins lymphoma. Proceedings of the Annual Meeting of the American Association for Cancer Research; Apr 2009; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract 30.

  27. Schnell R, Dietlein M, Staak JO, Borchmann P, Schomaecker K, Fischer T, et al. Treatment of refractory Hodgkin's lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibody. J Clin Oncol. 2005;23(21):4669–78. doi:10.1200/jco.2005.09.098.

    Article  PubMed  CAS  Google Scholar 

  28. Zhang M, Yao Z, Patel H, Garmestani K, Zhang Z, Talanov VS, et al. Effective therapy of murine models of human leukemia and lymphoma with radiolabeled anti-CD30 antibody, HeFi-1. Proc Natl Acad Sci USA. 2007;104(20):8444–8. doi:10.1073/pnas.0702496104.

    Article  PubMed  CAS  Google Scholar 

  29. Pasqualucci L, Wasik M, Teicher B, Flenghi L, Bolognesi A, Stirpe F, et al. Antitumor activity of anti-CD30 immunotoxin (Ber-H2/saporin) in vitro and in severe combined immunodeficiency disease mice xenografted with human CD30+ anaplastic large-cell lymphoma. Blood. 1995;85(8):2139–46.

    PubMed  CAS  Google Scholar 

  30. Falini B, Flenghi L, Aversa F, Barbabietola G, Martelli M, Comeli P, et al. Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin. Lancet. 1992;339(8803):1195–6.

    Article  PubMed  CAS  Google Scholar 

  31. Terenzi A, Bolognesi A, Pasqualucci L, Flenghi L, Pileri S, Stein H, et al. Anti-CD30 (BER=H2) immunotoxins containing the type-1 ribosome-inactivating proteins momordin and PAP-S (pokeweed antiviral protein from seeds) display powerful antitumour activity against CD30+ tumour cells in vitro and in SCID mice. Br J Haematol. 1996;92(4):872–9.

    Article  PubMed  CAS  Google Scholar 

  32. Bolognesi A, Tazzari PL, Olivieri F, Polito L, Falini B, Stirpe F. Induction of apoptosis by ribosome-inactivating proteins and related immunotoxins. Int J Cancer. 1996;68(3):349–55.

    Article  PubMed  CAS  Google Scholar 

  33. Schneix R, Linnartz C, Katouzi AA, Schon G, Bohlen H, Horn-Lohrens O, et al. Development of new ricin A-chain immunotoxins with potent anti-tumor effects against human hodgkin cells in vitro and disseminated Hodgkin tumors in scid mice using high-affinity monoclonal antibodies directed against the CD30 antigen. Int J Cancer. 1995;63(2):238–44. doi:10.1002/ijc.2910630216.

    Article  Google Scholar 

  34. Bolognesi A, Tazzari PL, Legname G, Olivieri F, Modena D, Conte R, et al. Anti-CD30 immunotoxins with native and recombinant dianthin 30. Cancer Immunol Immunother. 1995;40(2):109–14. doi:10.1007/bf01520292.

    Article  PubMed  CAS  Google Scholar 

  35. Barth S, Huhn M, Matthey B, Tawadros S, Schnell R, Schinköthe T, et al. Ki-4(scFv)–ETA′, a new recombinant anti-CD30 immunotoxin with highly specific cytotoxic activity against disseminated Hodgkin tumors in SCID mice. Blood. 2000;95(12):3909–14.

    PubMed  CAS  Google Scholar 

  36. Schnell R, Staak O, Borchmann P, Schwartz C, Matthey B, Hansen H, et al. A phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4.dgA) in patients with refractory CD30+ Hodgkin’s and non-Hodgkin’s lymphoma. Clin Cancer Res. 2002;8(6):1779–86.

    PubMed  CAS  Google Scholar 

  37. Francisco JA, Cerveny CG, Meyer DL, Mixan BJ, Klussman K, Chace DF, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003;102(4):1458–65. doi:10.1182/blood-2003-01-0039.

    Article  PubMed  CAS  Google Scholar 

  38. Doronina SO, Toki BE, Torgov MY, Mendelsohn BA, Cerveny CG, Chace DF, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol. 2003;21(7):778–84.

    Article  PubMed  CAS  Google Scholar 

  39. Sanderson RJ, Hering MA, James SF, Sun MMC, Doronina SO, Siadak AW, et al. In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate. Clin Cancer Res. 2005;11(2):843–52.

    PubMed  CAS  Google Scholar 

  40. • Okeley NM, Miyamoto JB, Zhang X, Sanderson RJ, Benjamin DR, Sievers EL, et al. Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Clin Cancer Res. 2010;16(3):888–97. doi:10.1158/1078-0432.ccr-09-2069. This article describes the mechanism of action of brentuximab vedotin.

    Article  PubMed  CAS  Google Scholar 

  41. Lambert JM. Drug-conjugated monoclonal antibodies for the treatment of cancer. Curr Opin Pharmacol. 2005;5(5):543–9. doi:10.1016/j.coph.2005.04.017.

    Article  PubMed  CAS  Google Scholar 

  42. • Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010;363(19):1812–21. doi:10.1056/NEJMoa1002965. First-in-human study of brentuximab vedotin.

    Article  PubMed  CAS  Google Scholar 

  43. • Fanale M, Bartlett NL, Forero-Torres A, Rosenblatt J, Horning SJ, Franklin AR, et al. The antibody-drug conjugate brentuximab vedotin (SGN-35) induced multiple objective responses in patients with relapsed or refractory CD30-positive lymphomas in a phase 1 weekly dosing study. Blood (Ash Annual Meeting Abstracts). 2009;114, abstract 2731. Safety and activity of brentuximab vedotin given in a weekly regimen.

  44. •• Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012;30(18):2190–6. doi:10.1200/jco.2011.38.0402. Pivotal phase II trial of brentuximab vedotin in relapsed refractory sALCL.

    Article  PubMed  CAS  Google Scholar 

  45. Hombach A, Jung W, Pohl C, Renner C, Sahin U, Schmits R, et al. A CD16/CD30 bispecific monoclonal antibody induces lysis of Hodgkin's cells by unstimulated natural killer cells in vitro and in vivo. Int J Cancer. 1993;55(5):830–6.

    Article  PubMed  CAS  Google Scholar 

  46. Wu Y. Session 11: Therapeutic antibodies. Hum Antibodies. 2011;20(3–4):61–3.

    Google Scholar 

  47. Knackmuss S, Reusch U, Burkhardt C, Fucek I, Le Gall F, Pauels H-G, et al. Preclinical development of an anti-CD30/anti-CD16A bispecific tetravalent TandAb antibody for the treatment of Hodgkin lymphoma. ASCO Meeting Abstracts. 2012;30(15 suppl). e18532.

  48. Rothe A, Younes A, Reiners KS, Dietlein M, Eichenauer DA, Kessler J, et al. A phase I study with the bispecific anti-CD30 x anti-CD16A antibody construct AFM13 in patients with relapsed or refractory hodgkin lymphoma. Blood (ASH Annual Meeting Abstracts). 2011;118(21):Abstract 3709.

  49. Shapiro R, Riordan JF, Vallee BL. Characteristic ribonucleolytic activity of human angiogenin. Biochemistry. 1986;25(12):3527–32. doi:10.1021/bi00360a008.

    Article  PubMed  CAS  Google Scholar 

  50. Barth S, Matthey B, Huhn M, Diehl V, Engert A. CD30L-ETA': a new recombinant immunotoxin based on the CD30 ligand for possible use against human lymphoma. Cytokines Cell Mol Ther. 1999;5(2):69–78.

    PubMed  CAS  Google Scholar 

  51. Huhn M, Sasse S, Tur MK, Matthey B, Schinköthe T, Rybak SM, et al. Human angiogenin fused to human CD30 ligand (Ang-CD30L) exhibits specific cytotoxicity against CD30-positive lymphoma. Cancer Res. 2001;61(24):8737–42.

    PubMed  CAS  Google Scholar 

  52. Roskrow MA, Suzuki N, Gan Y-J, Sixbey JW, Ng CYC, Kimbrough S, et al. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease. Blood. 1998;91(8):2925–34.

    PubMed  CAS  Google Scholar 

  53. Bollard CM, Aguilar L, Straathof KC, Gahn B, Huls MH, Rousseau A, et al. Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease. J Exp Med. 2004;200(12):1623–33. doi:10.1084/jem.20040890.

    Article  PubMed  CAS  Google Scholar 

  54. Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci USA. 1993;90(2):720–4.

    Article  PubMed  CAS  Google Scholar 

  55. Hombach A, Heuser C, Sircar R, Tillmann T, Diehl V, Pohl C, et al. An Anti-CD30 chimeric receptor that mediates CD3-zeta-independent T-cell activation against Hodgkin's lymphoma cells in the presence of soluble CD30. Cancer Res. 1998;58(6):1116–9.

    PubMed  CAS  Google Scholar 

  56. ClinicalTrials.gov. Administration of T lymphocytes for Hodgkin's lymphoma and non-Hodgkin's lymphoma (CART CD30). http://clinicaltrials.gov/ct2/show/NCT01316146. Accessed 10 Sept 2012.

  57. Brocker T, Karjalainen K. Signals through T cell receptor-zeta chain alone are insufficient to prime resting T lymphocytes. J Exp Med. 1995;181(5):1653–9. doi:10.1084/jem.181.5.1653.

    Article  PubMed  CAS  Google Scholar 

  58. Brocker T. Chimeric Fv-ζ or Fv-ε receptors are not sufficient to induce activation or cytokine production in peripheral T cells. Blood. 2000;96(5):1999–2001.

    PubMed  CAS  Google Scholar 

  59. ClinicalTrials.gov. EBV CTLs expressing CD30 chimeric receptors for CD 30+ lymphoma (CARCD30). http://clinicaltrials.gov/ct2/show/NCT01192464. Accessed 10 Sept 2012.

Download references

Disclosure

J. Vadakara: none; B. Pro: consultant for Celgene, Spectrum, and Allos, pending grant/research funds from Seattle Genetics, and honoraria from Celgene and Allos.

Author information

Authors and Affiliations

  1. Fox Chase Cancer Center, Philadelphia, PA, USA

    Joseph Vadakara & Barbara Pro

Authors
  1. Joseph Vadakara
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Barbara Pro
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Barbara Pro.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vadakara, J., Pro, B. Targeting CD30 in Anaplastic Large Cell Lymphoma. Curr Hematol Malig Rep 7, 285–291 (2012). https://doi.org/10.1007/s11899-012-0137-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11899-012-0137-y

Keywords

Search

Navigation